Heron Therapeutics Reports Strong Acute Care Growth, Issues Positive 2026 Revenue & Adjusted EBITDA Guidance
HRTX is trading near its 52-week low of $1 (8.0% above the low) on elevated volume (3.1× avg).
Summary
Heron Therapeutics announced Q4 and full-year 2025 financial results, showcasing robust growth in its Acute Care franchise and providing optimistic 2026 revenue and adjusted EBITDA guidance.
Key Events · Earnings and Guidance · HRTX
-
Strong Acute Care Franchise Growth
The Acute Care franchise, including ZYNRELEF and APONVIE, achieved 65.1% year-over-year net revenue growth in 2025, reaching $49.6 million.
-
Full-Year 2025 Revenue Achieved
Heron Therapeutics reported $154.9 million in total net revenue for full-year 2025, representing a 7.4% increase compared to 2024.
-
Positive 2026 Financial Guidance Issued
The company issued full-year 2026 net revenue guidance of $173 to $183 million and adjusted EBITDA guidance of $10 to $20 million, indicating expected profitability on an adjusted basis.
-
Key Product Milestones Achieved
CMS approved permanent, product-specific J-Codes for both ZYNRELEF (J0668) and APONVIE (J8502), effective October 1, 2025, which is expected to streamline reimbursement and improve billing clarity.
Analysis · HRTX · Life Sciences
Heron Therapeutics announced its full financial results for Q4 and full-year 2025, following preliminary revenue figures released on January 9, 2026. The company demonstrated robust growth in its Acute Care franchise, driven by ZYNRELEF and APONVIE, which saw a 65.1% year-over-year revenue increase in 2025. Despite an overall net loss for the year, the company provided optimistic 2026 guidance, projecting significant revenue growth and a return to positive Adjusted EBITDA. Key product milestones, including the approval of permanent J-Codes for both ZYNRELEF and APONVIE, are expected to streamline reimbursement and accelerate adoption, positioning the company for continued commercial expansion.
At the time of this filing, HRTX was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $198M. The 52-week trading range was $1.00 to $2.68. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.